DPP4 and type 2 diabetes mellitus: However, the generalisability of these results does not necessarily extend to those at higher risk for cognitive decline, or to those with MMSE <24, and we also cannot extrapolate the results to individuals with more advanced type 2 diabetes, or to other DPP-4 inhibitors or sulfonylureas.